Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2018 from OUS - Section of Preventive Medicine
30 publications found
Dietary intake and blood concentrations of antioxidants and the risk of cardiovascular disease, total cancer, and all-cause mortality: a systematic review and dose-response meta-analysis of prospective studies
Am J Clin Nutr, 108 (5), 1069-1091
DOI 10.1093/ajcn/nqy097, PubMed 30475962
Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial
JAMA Intern Med, 178 (5), 622-631
DOI 10.1001/jamainternmed.2018.0397, PubMed 29630702
Inflammatory and Cholesterol Risk in the FOURIER Trial
Circulation, 138 (2), 131-140
DOI 10.1161/CIRCULATIONAHA.118.034032, PubMed 29530884
Exploring the effect of a lifestyle intervention on cancer risk: 43-year follow-up of the randomized Oslo diet and antismoking study
J Intern Med, 284 (3), 282-291
DOI 10.1111/joim.12765, PubMed 29790221
Effect of strenuous exercise on mediators of inflammation in patients with coronary artery disease
Cytokine, 105, 17-22
DOI 10.1016/j.cyto.2018.02.006, PubMed 29433015
Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial
J Clin Lipidol, 13 (1), 138-147
DOI 10.1016/j.jacl.2018.11.007, PubMed 30591415
Physical fitness is a modifiable predictor of early cardiovascular death: A 35-year follow-up study of 2014 healthy middle-aged men
Eur J Prev Cardiol, 25 (15), 1655-1663
DOI 10.1177/2047487318793459, PubMed 30103630
Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program
Atherosclerosis, 278, 307-314
DOI 10.1016/j.atherosclerosis.2018.08.036, PubMed 30293878
Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study
J Clin Lipidol, 12 (5), 1199-1207
DOI 10.1016/j.jacl.2018.05.007, PubMed 30318065
Sex differences in cholesterol levels from birth to 19 years of age may lead to increased cholesterol burden in females with FH
J Clin Lipidol, 12 (3), 748-755.e2
DOI 10.1016/j.jacl.2018.02.021, PubMed 29609857
Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia
J Clin Lipidol, 12 (6), 1463-1470
DOI 10.1016/j.jacl.2018.08.011, PubMed 30287210
Risk of Ischemic Stroke and Total Cerebrovascular Disease in Familial Hypercholesterolemia
Stroke, 50 (1), 172-174
DOI 10.1161/STROKEAHA.118.023456, PubMed 30580708
Prevalence of diabetes before and after first diagnosis of coronary artery disease
Tidsskr Nor Laegeforen, 138 (5)
DOI 10.4045/tidsskr.17.0539, PubMed 29513466
Are PCSK9 Inhibitors Cost Effective?
Pharmacoeconomics, 36 (9), 1031-1041
DOI 10.1007/s40273-018-0671-0, PubMed 29777433
Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial
JAMA Cardiol, 3 (8), 749-753
DOI 10.1001/jamacardio.2018.1533, PubMed 29898218
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials)
Am J Cardiol, 121 (8), 940-948
DOI 10.1016/j.amjcard.2017.12.040, PubMed 29472008
Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks
Eur Heart J, 39 (24), 2243-2251
DOI 10.1093/eurheartj/ehx760, PubMed 29365085
Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia
Heart, 104 (19), 1600-1607
DOI 10.1136/heartjnl-2017-312706, PubMed 29622598
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial
Clin Cardiol, 41 (10), 1281-1288
DOI 10.1002/clc.23055, PubMed 30125052
The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions
Heart Fail Rev, 23 (3), 303-323
DOI 10.1007/s10741-018-9685-0, PubMed 29516230
Effect of low carbohydrate high fat diet on LDL cholesterol and gene expression in normal-weight, young adults: A randomized controlled study
Atherosclerosis, 279, 52-61
DOI 10.1016/j.atherosclerosis.2018.10.013, PubMed 30408717
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease
Circulation, 138 (8), 756-766
DOI 10.1161/CIRCULATIONAHA.118.034309, PubMed 29626068
Evaluation of a short Food Frequency Questionnaire to assess cardiovascular disease-related diet and lifestyle factors
Food Nutr Res, 62
DOI 10.29219/fnr.v62.1370, PubMed 29720928
A randomized controlled trial in Norwegian pharmacies on effects of risk alert and advice in people with elevated cardiovascular risk
Prev Med Rep, 12, 79-86
DOI 10.1016/j.pmedr.2018.08.004, PubMed 30191097
Non-invasive hemodynamic monitoring as a guide to drug treatment of uncontrolled hypertensive patients: effects on home blood pressure in the BEAUTY study
Blood Press, 27 (6), 368-375
DOI 10.1080/08037051.2018.1505425, PubMed 30129785
Coding variants in RPL3L and MYZAP increase risk of atrial fibrillation
Commun Biol, 1, 68
DOI 10.1038/s42003-018-0068-9, PubMed 30271950
Familial hypercholesterolemia and young patients' thoughts on own condition and treatment
Patient Educ Couns, 102 (5), 1005-1012
DOI 10.1016/j.pec.2018.12.025, PubMed 30606641
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Lancet, 392 (10155), 1311-1320
DOI 10.1016/S0140-6736(18)31652-0, PubMed 30293769
2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension
Blood Press, 27 (6), 314-340
DOI 10.1080/08037051.2018.1527177, PubMed 30380928
Interleukin-18 and the NLR family pyrin domain containing-3 inflammasome in adipose tissue are strongly associated with glucometabolic variables in a cohort of middle-aged men
Diab Vasc Dis Res, 15 (5), 458-464
DOI 10.1177/1479164118785307, PubMed 29972041